Skip to content
Search

Latest Stories

Obesity drug could reduce heart attack risk, study finds

The trial, involving 17,604 patients, evaluated Wegovy not for weight loss but for its heart-protective benefits in overweight and obese individuals.

Obesity drug could reduce heart attack risk, study finds

An obesity drug has been found to decrease the risk of heart attacks, strokes, or heart failure in obese individuals regardless of the amount of weight they lose while on the medication, according to researchers.

The study of the drug, Wegovy, revealed that participants maintained significant weight loss over four years, with fewer serious adverse events compared to those given placebo treatment, reported Sky News.


These findings may prompt UK health authorities, which currently limit treatment to two years, to reconsider their policies.

The Danish drugmaker presented the new long-term data on Tuesday at the European Congress on Obesity in Venice, Italy, in a new analysis from a large study for which substantial results had been published last year, reported Reuters.

On average, participants lost 10.2 per cent of their body weight and 7.7 cm from their waist size after four years.

Even individuals with mild obesity or modest weight loss experienced cardiovascular benefits, suggesting potential broader effects of the treatment beyond fat reduction.

The study, led by Professor John Deanfield of University College London (UCL), utilised data from the Select trial conducted by Wegovy manufacturer Novo Nordisk.

Semaglutide, the active ingredient in Wegovy, belongs to a class of GLP-1 drugs that suppress appetite, aiding in calorie reduction.

The trial, involving 17,604 patients, evaluated Wegovy not for weight loss but for its heart-protective benefits in overweight and obese individuals with preexisting heart disease but without diabetes. Participants were not required to monitor diet and exercise as it was not focused on obesity, Reuters reported.

Around 17 per cent of trial participants discontinued Wegovy use due to side effects, primarily nausea, according to Novo's analysis.

Patients in the Select trial lost an average of nearly 10 per cent of their total body weight after 65 weeks on Wegovy. This weight loss was maintained year on year, reaching 10.2 per cent after approximately four years, as reported by the company.

Another analysis by Novo, also released on Tuesday, demonstrated that Wegovy's heart-protective benefits were consistent regardless of patients' initial weight or the amount of weight they lost on the drug.

"We now also understand that while we know that body weight loss is important, it's not the only thing driving the cardiovascular benefit of semaglutide treatment," Lange told Reuters in an interview.

The Select study revealed that Wegovy reduced the risk of major cardiovascular events such as strokes by 20 per cent in overweight or obese individuals with a history of heart disease. This news led to a 13 per cent surge in Novo shares to record highs upon its release in August.

Novo continues to investigate the mechanisms behind semaglutide's cardiovascular protection.

Wegovy and Zepbound are undergoing testing to evaluate their benefits in various medical conditions such as reducing heart attack risk, treating sleep apnea, and managing kidney disease.

More For You

Sri Lanka forms committee to address UK sanctions
Anura Kumara Dissanayake

Sri Lanka forms committee to address UK sanctions

THE Sri Lanka government on Wednesday (2) formed a committee to recommend measures regarding the UK's decision to impose sanctions on three former military commanders who led the campaign that crushed the Liberation Tigers of Tamil Eelam (LTTE) in 2009.

Health minister Nalinda Jayatissa told reporters that foreign minister Vijitha Herath, justice minister Harshana Nanayakkara and deputy minister of defence Aruna Jayasekara would comprise the committee that would consult experts for the purpose.

Keep ReadingShow less
Gujarat-blast-ANI

The blast caused the factory’s concrete roof to collapse, scattering debris and body parts across the area, officials confirmed. (Photo: ANI)

ANI

Death toll rises to 21 in Gujarat firework factory explosion

AN EXPLOSION at an illegal firecracker factory in Gujarat's Deesa town killed 21 people and injured several others on Tuesday, officials said.

The blast caused the factory’s concrete roof to collapse, scattering debris and body parts across the area, officials confirmed.

Keep ReadingShow less
Child benefit payments set to rise for UK families

Child benefit, normally paid every four weeks directly into bank accounts, has undergone significant changes in recent months (Photo: Getty Images)

Child benefit payments set to rise for UK families

MILLIONS of British families are set to receive a financial boost as child benefit payments increase from April 7, according to HM Revenue and Customs (HMRC).

From next week, parents will receive £26.05 per week for the eldest or only child, amounting to £1,354.60 annually - up from the current rate of £25.60. For each additional child, payments will rise to £17.25 weekly, totalling £897 per year - an increase from the present £16.95 rate. This represents a 1.7 per cent increase across all payment categories.

Keep ReadingShow less
Anant Ambani Walks 140 Km in Spiritual Tribute on 30th Birthday

Anant’s padyatra is a reflection of the larger cultural fabric of India

Getty

Anant Ambani embarks on a 140-kilometer spiritual journey on foot to celebrate 30th birthday

Anant Ambani, a director of Reliance Industries Limited and a prominent figure in Indian industry, has chosen a unique and spiritual way to mark his 30th birthday. As part of his celebrations, he is currently undertaking a padyatra—a traditional pilgrimage on foot—from Jamnagar to Dwarka, covering a distance of approximately 140 kilometres. The journey reflects his devotion to Lord Dwarkadhish, the presiding deity of the Dwarkadhish Temple in the city of Dwarka.

Anant began his journey from his family’s residence in Moti Khavdi, Jamnagar, and has been progressing steadily for the past five days. Walking an estimated 10-12 kilometres each night, he travels under the protection of Z+ security and local police, ensuring his safety during this significant journey. The padyatra is expected to take between seven to nine days in total, with plans to conclude at the Dwarkadhish Temple in time for his birthday on April 10.

Keep ReadingShow less
New TB action plan proposed as cases surge

Government urged experts to come forward to help draw up a new five-year TB action plan. (Photo: Getty Images)

New TB action plan proposed as cases surge

BRITAIN on Wednesday (2) urged health experts and sufferers of tuberculosis (TB) to come forward to help draw up a new five-year action plan as it deals with record rises in the disease.

In 2023, England recorded its largest annual increase (11 per cent) in cases since enhanced surveillance began in 2000.

Keep ReadingShow less